D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.7B |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$880M |
| 3 |
Boeing
BA
|
+$850M |
| 4 |
Eli Lilly
LLY
|
+$689M |
| 5 |
Tesla
TSLA
|
+$665M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$964M |
| 2 |
Apple
AAPL
|
+$606M |
| 3 |
Workday
WDAY
|
+$520M |
| 4 |
Palantir
PLTR
|
+$514M |
| 5 |
Spotify
SPOT
|
+$431M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.54% |
| 2 | Consumer Discretionary | 8.87% |
| 3 | Healthcare | 8.21% |
| 4 | Financials | 5.68% |
| 5 | Industrials | 4.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4001
CALL
Neumora Therapeutics
NMRA
$276M
| $133K | ﹤0.01% |
+12,500
| New | +$150K |
|
4002
CALL
Hecla Mining
HL
$10.2B
| $131K | ﹤0.01% |
+26,600
| New | +$159K |
|
4003
Nuvation Bio
NUVB
$2.24B
| $126K | ﹤0.01% |
47,400
-63,827
| -57% | -$164K |
|
4004
CALL
Blink Charging
BLNK
$75.2M
| $125K | ﹤0.01% |
90,000
| – | – |
|
4005
LG Display
LPL
$3.17B
| $122K | ﹤0.01% |
+39,902
| New | +$141K |
|
4006
Lifezone Metals Ltd Warrants
LZM.WS
| $122K | ﹤0.01% |
166,366
| – | – |
|
4007
Kosmos Energy
KOS
$1.56B
| $122K | ﹤0.01% |
35,700
+20,700
| +138% | +$78.8K |
|
|
AVDL
4008
PUT
DELISTED
Avadel Pharmaceuticals
AVDL
| $122K | ﹤0.01% |
+11,600
| New | +$141K |
|
4009
Barings BDC
BBDC
$862M
| $122K | ﹤0.01% |
+12,737
| New | +$125K |
|
|
HCVIW
4010
DELISTED
Hennessy Capital Investment Corp. VI Warrant
HCVIW
| $120K | ﹤0.01% |
990,000
| – | – |
|
4011
PUT
Ecopetrol
EC
$32.9B
| $120K | ﹤0.01% |
+15,100
| New | +$122K |
|
4012
EverCommerce
EVCM
$2.05B
| $119K | ﹤0.01% |
+10,782
| New | +$120K |
|
4013
CALL
Goodyear
GT
$2.07B
| $117K | ﹤0.01% |
13,000
| – | – |
|
4014
Allogene Therapeutics
ALLO
$601M
| $116K | ﹤0.01% |
54,517
-35,808
| -40% | -$88.3K |
|
4015
Veritone
VERI
$96.7M
| $116K | ﹤0.01% |
35,244
-151,780
| -81% | -$492K |
|
|
VTYX
4016
DELISTED
Ventyx Biosciences
VTYX
| $114K | ﹤0.01% |
52,231
-54,437
| -51% | -$123K |
|
|
THRD
4017
DELISTED
Third Harmonic Bio
THRD
| $113K | ﹤0.01% |
11,000
-2,967
| -21% | -$37K |
|
4018
Tilly's
TLYS
$115M
| $113K | ﹤0.01% |
26,510
| – | – |
|
4019
Arteris
AIP
$1.4B
| $110K | ﹤0.01% |
+10,773
| New | +$89K |
|
4020
Radiant Logistics
RLGT
$416M
| $109K | ﹤0.01% |
16,328
-5,557
| -25% | -$38.3K |
|
4021
Stagwell
STGW
$1.84B
| $109K | ﹤0.01% |
+16,578
| New | +$118K |
|
4022
Marqeta
MQ
$1.8B
| $106K | ﹤0.01% |
6,987
-89,126
| -93% | -$1.56M |
|
|
SBDS
4023
DELISTED
Solo Brands Inc
SBDS
| $104K | ﹤0.01% |
2,284
+5
| +0.2% | +$248 |
|
|
ARI
4024
Apollo Commercial Real Estate
ARI
$887M
| $103K | ﹤0.01% |
11,841
-17,753
| -60% | -$160K |
|
|
ATXS
4025
DELISTED
Astria Therapeutics
ATXS
| $102K | ﹤0.01% |
11,375
+1,207
| +12% | +$12.8K |
|
Similar funds
D.E. Shaw & Co's Q4 2024 Portfolio in Review
As of Q4 2024, D.E. Shaw & Co held 5,079 positions worth $136B, up 17% from $116B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
D.E. Shaw & Co deployed $10.6B of net new capital in Q4 2024, opening 591 new positions and adding to 1,620 existing holdings. Its largest new stake was Lam Research: 3,525,438 shares worth $255M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 15% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was NVIDIA, an estimated $964M trimmed.
- D.E. Shaw & Co's largest Q4 2024 buy was Lam Research: 3,525,438 shares worth $255M.
- D.E. Shaw & Co added most to State Street SPDR S&P 500 ETF Trust in Q4 2024, an estimated $3.7B increase.
- D.E. Shaw & Co's biggest Q4 2024 reduction was NVIDIA, cutting an estimated $964M.
- D.E. Shaw & Co fully exited Marathon Oil Corporation in Q4 2024, selling an estimated $81.4M.
- D.E. Shaw & Co's ten largest holdings make up 11% of its $136B portfolio in Q4 2024.
- D.E. Shaw & Co opened 591 new positions and closed 731 in Q4 2024.
- D.E. Shaw & Co's portfolio value rose 17% quarter-over-quarter to $136B.
Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.